MartinBorchJensen

SUBJECT SUMMARY

Scientist identifying bottlenecks in longevity drug development and building organizations to address them.

Co-founder & CSO, Gordian Biotechnology Founder & President, Norn Group

TECHNOLOGY
Target abundance through pooled in vivo screening in living models of age-related disease.
STRATEGY
Address key bottlenecks to industrializing longevity so the field’s productivity can compound.
COUNCIL ON INNOVATION & PROGRESS
DOCUMENT TYPEBIOGRAPHICAL FILE
FILE NO.CIP–11–MBJ–THREAD
SUBJECTMARTIN BORCH JENSEN
DATE PREPARED01 AUG 2026
ORIGINATING DESKFRONTIER FIELDS DESK
REVIEW BASISCAPACITY TO PROGRESS A FIELD
OBSERVATION WINDOW2011 → PRESENT
PRIMARY FIELDLONGEVITY
FORM CIP–1200
ACTIVE REVIEW

FIELD ADVANCEMENT · 02 AUG 2026

Historical anatomical section through the human heart, lungs and thorax
FIG. 1 / CARDIOPULMONARY SECTIONGRAY / CARTER · 1918 · PUBLIC DOMAIN
1911 perspective routing diagram showing paths followed while manufacturing principal automobile units
FIG. 4 / MANUFACTURING ROUTINGDAY · 1911 · PUBLIC DOMAIN (U.S.)
Historical highly magnified drawing of human bone marrow
FIG. 2 / BONE-MARROW HISTOLOGYGRAY / CARTER · 1918 · PUBLIC DOMAIN
Critical-path network diagram showing operational sequence, concurrent work and dependencies
FIG. 3 / PROCESS FLOW + CRITICAL PATHU.S. DOT / FHWA · PUBLIC DOMAIN (U.S.)
ATTACHMENT A–01 Martin Borch Jensen outdoors in a Gordian Biotechnology shirt
SUBJECT, CURRENT · SOURCE: SUBJECT’S PUBLIC SITE · PHOTOGRAPHER NOT RECORDED
OPEN DOSSIER 01 / WHO IS MARTIN? ↓
01 / CURRENT ASSESSMENT

Who is Martin?

Martin Borch Jensen approaches longevity drug development as a set of practical bottlenecks, some addressable within a company and others requiring field-level coordination. Gordian Biotechnology addresses the rate of discovery: pooled in vivo screens compare hundreds of interventions in living disease and help identify which targets are worth pursuing. Norn Group maps and targets the surrounding field constraints, including missing benchmarks, tools, incentives and talent. The broader goal is to industrialize longevity: to build a field capable of producing effective interventions faster than age-related decline advances. His research in DNA repair, mitochondrial function, NAD metabolism and cellular stress grounds this work in experimental aging biology.

SOURCE MIX: ACADEMIC RECORD · COMPANY ACCOUNT · NONPROFIT PROGRAM RECORD Assessment synthesized from public sources · reviewed 01 AUG 2026
02 / OPERATING RECORD

Systematic therapeutic discovery

The Gordian Biotechnology team outside the company facility; Martin Borch Jensen’s full visible figure is marked by a twice-drawn green pen oval in the back row at left, raising a black blade
ATTACHMENT G–01 · GORDIAN TEAM AT COMPANY FACILITY · MARTIN RINGED IN GREEN · PHOTOGRAPH © NINO SOLANO · FIELD ARCHIVE COPY
PRIVATE COMPANY, EST. 2018

Gordian Biotechnology

Co-founder & chief scientific officer

Drug discovery produces more possible targets than researchers can test in living disease. Gordian narrows that gap by testing many interventions in parallel in diseased animals. Single-cell transcriptomes from each perturbation are scored against molecular features built from paired datasets linking molecular patterns to measured physiology, along with patient data and established disease biology. Interventions can then be ranked across shared disease-relevant axes such as fibrosis, inflammation and regeneration.

MOSAIC SCREENING Mosaic Screening tests hundreds of barcoded therapies in a living diseased animal. It measures the cell-state changes produced by each therapy and scores them across multiple physiological measures.

PAPER, FEB 2026 ↗Mouse pulmonary fibrosis and naturally arthritic aged horses; predictions tested in human tissue.

CURRENT PIPELINE ↗OA program headed to clinic; discovery across cardiometaborenal disease.

OPERATING PROOF, 2026Pfizer collaboration · in-vivo target discovery for obesity ↗

Open Gordian science record →
01Disease contextTest in living disease models.
02ThroughputCompare many interventions in parallel.
03Predictive validityTest whether screen predictions hold in human tissue.
03 / FIELD-BUILDING RECORD

Longevity Infrastructure

NONPROFIT, EST. 2021

Norn Group

Founder & president

Norn builds the field infrastructure needed to turn longevity science into medicines that extend healthy human life. It maps what blocks progress, funds critical efforts that existing systems overlook, and designs programs targeting key bottlenecks to industrializing longevity. The aim is a legible path from evidence to people, benchmarks that validate therapeutic potential, and research infrastructure, tools and incentives that allow progress to compound.

REPORTED IMPACT, AUG 2026Impetus: $34M+ across 146 projects · Norn: 200+ papers and more than two dozen new labs in longevity ↗

Source: Norn impact record, accessed 02 AUG 2026. Open Norn record →

Impetus Grants now focused on AI-enabling datasets

Martin Borch Jensen presenting beside a slide titled The numbers defining progress in longevity
ATTACHMENT N–01 · “FOUR NUMBERS DEFINE PROGRESS IN LONGEVITY” · PROGRESS CONFERENCE 2025 · VIDEO FRAME: ROOTS OF PROGRESS INSTITUTE
PROGRAM 01Impetus GrantsFast funding for high-impact research ideas
PROGRAM 02Talent BridgeBringing talent to US longevity labs
PROGRAM 03Clock Assessment ProgramBenchmarking aging clocks against lifespan
PAST PROGRAM, 2021

Longevity Apprenticeship

Norn’s first talent program paired early-career contributors with expert mentors and hands-on longevity projects; it helped launch Impetus Grants. Norn impact record ↗

Replaced by Norn Nexus?

04 / PUBLIC RECORDS

Corpus

ARC OF RESEARCH
  1. DNA repair Bohr
  2. Mitochondrial stress Jasper
  3. Physiological circuits Independent
  4. In vivo screening Independent
RECORD SET 02

Broad audience talks

SELECTED STAGE PRESENTATIONS

RECORD SET 03

Interviews

Podcasts, hosted conversations and direct Q&As

05 / ASSOCIATES

Associates

Scroll horizontally to inspect the full evidence board.

Martin Borch Jensen speaking from the audience at the 2025 Genetic Agency and Technology Conference
SUBJECT / 001–MBJMartin
Martin Borch Jensen and Francisco LePort beside their art car at Burning Man in 2018
Francisco LePort GORDIAN CO-FOUNDER
Adam Marblestone at The Institute Tom Kalil speaking at a public-policy symposium Kumar Garg
Adam Marblestone · Tom Kalil · Kumar Garg ALIGNED ON SCIENCE PROGRESS
Lada Nuzhna
Lada Nuzhna LONGEVITY
Juan Benet speaking to an audience at Web3 Summit
Juan Benet FRIEND + SUPPORTER
Jenna Hermann of Jenergy Labs
Jenna Hermann PARTNER
Tara Mei, a Longevity Apprentice Marton Meszaros, a Norn community member Madison Ueland, a Norn Nexus member Wyatt Morgan, a Norn Nexus member
Norn community + Longevity Apprentices MENTORS + CONVENES
Alliance for Longevity Initiatives mark James Fickel Robert Rosenkranz
A4LI · James Fickel · Robert Rosenkranz ADVISES
Jerôme Baltzersen
Jerôme Baltzersen
Raza Habib and Alex Page standing together in a garden
Raza Habib & Alex Page
SIGHTING / 01 Conference attendees talking in the Lighthaven garden beneath shade sails and a timber pergola in Berkeley
Lighthaven
SIGHTING / 02 Overhead street map of Dogpatch, San Francisco, centered on Third Street and Pier 70
Dogpatch
SIGHTING / 03 The Palace of Fine Arts rotunda glowing at blue hour, with an event tent beneath the illuminated arches
Palace of Fine Arts
SIGHTING / 04 Evening storefront of Udupi Palace on Valencia Street in San Francisco's Mission District
Udupi Palace
Martin Borch Jensen and Jenna Hermann in costume at an unidentified wood-paneled location
Image sources

IMAGE SOURCES · CURRENT RECORD · SUBJECT · GATC 2025 · GORDIAN · BURNING MAN 2018 · NORN · IMPETUS ARCHIVE · NORN COMMUNITY ARCHIVE · JENERGY LABS · THE INSTITUTE · MARBLESTONE · ASME · KALIL · CMU · GARG · PROTOCOL LABS · BENET · A4LI · DGI · BALTZERSEN · USER PHOTO · HABIB + PAGE · UNIDENTIFIED INTERIOR SNAPSHOT · LIGHTHAVEN · EA FORUM · DOGPATCH MAP · © OSM CONTRIBUTORS · PALACE · F. SCHULENBURG · CC BY-SA 3.0 · UDUPI PALACE · T. GRATHWELL · CC BY 4.0

06 / BACKGROUND

Biographical Arc

  1. University of Copenhagen / National Institute on AgingPhD / DNA repair, mitochondrial function and accelerated aging
    EliteForsk scholarship, 2011
  2. Danish Air ForceMilitary service
  3. Buck InstitutePostdoctoral research / mechanisms of aging
    Benzon Scholarship, 2013
    NIH K99/R00 Pathway to Independence, 2017
  4. Gordian BiotechnologyCo-founder & CSO / pooled in-vivo therapeutic discovery
  5. Norn GroupFounder & President / longevity infrastructure and field strategy

Martin left Denmark for the United States because he believed it offered the greatest potential for serious work on aging. He went to the National Institute on Aging expecting a plan to cure aging, but learned that this wasn't even the goal. So he set about understanding aging well enough to formulate a plan himself.

By 2017, the K99/R00 offered a clear route to an independent academic lab. He formally returned the award and left academia in 2018 because another lab could not address the scale of the problem. Gordian tackled the rate of therapeutic discovery. As he came to know the field more broadly, the absence of a field-level plan became harder to ignore, leading to Norn in 2021.

Source trail: Gordian founding history, University of Copenhagen thesis record, archived EliteForsk record, NIH RePORTER K99 record, and Norn biography.

SUPPLEMENTARY MATERIAL
Close view of a residential shelf with texts spanning systems biology, medicine, political economy and fiction
SUPPORTING EVIDENCE

Formative texts

  1. 01Schismatrix
  2. 02Count of Monte Cristo
  3. 03Paul Graham
  4. 04Tom Kirkwood
  5. 05Systems Medicine
  6. 06Parable of the Sower
  7. 07Benjamin Franklin
  8. 08You and Your Research
EARLY RECORD, 2011

The waste of a life cut short

An archived EliteForsk profile traces Martin’s interest in aging to high school. He chose aging research because the loss of healthy life seemed like a problem science might be able to change.

Martin Borch Jensen working at a laboratory bench during his PhD
ATTACHMENT P-01 · COPENHAGEN LABORATORY · C. 2011
Martin Borch Jensen, then-Crown Prince Frederik, and a fellow recipient at the 2011 EliteForsk ceremony
ATTACHMENT P-02 · ELITEFORSK CEREMONY · 2011
MISSING PAPER TRAIL, 2011–2014

The fasting years

  1. Practices alternate-day fasting for several years.

  2. Weekendavisen and Berlingske Tidende take an interest. Smaller articles and radio appearances follow. Records missing.

  3. Samvirke: “Jeg spiser kun hver anden dag”; the trail ends in the book 1-dagskuren.

Unverified projects

UNVERIFIED PROJECTS
07 / CURRENT THREADS

What is he thinking about?

ATTACHMENT I–01 · EXPERIMENT DESIGN Martin Borch Jensen onstage at Vitalist Bay pointing to a slide titled Design experiments for the future Design experiments for the futureVITALIST BAY · MAY 2026 ↗
Diagram linking molecular, cellular, organ and organismal layers upward to real-world readouts; automation scales molecular and cellular measurements, while AlphaFold predicts protein structure rather than cell state
08 / FIELD REPORT

Recent sighting

RECOVERED EVENT PROFILE, PMWC 2026 Precision Medicine World Conference
Public event portrait of Martin Borch Jensen
SPEAKER PROFILE

Martin Borch Jensen

Co-founder & Chief Science Officer · Gordian Biotechnology
President · Norn Group

Martin Borch Jensen builds systems to accelerate progress in longevity. At Gordian Biotechnology, he develops pooled in-vivo genetic screening in patient-relevant animals to generate systematic evidence about what works in complex biology. Through Norn Group, he builds rapid research funding, talent programs and shared infrastructure for high-risk longevity work outside traditional mechanisms.

TRACK
Precision Aging & Longevity
TALK
The Data We Need for AI to Accelerate Longevity Drugs